key: cord-0311496-seehb6f2
authors: Mangione, William; Falls, Zackary; Samudrala, Ram
title: Effective holistic characterization of small molecule effects using heterogeneous biological networks
date: 2022-04-06
journal: bioRxiv
DOI: 10.1101/2022.03.23.485550
sha: d0e67caceb2b2a7859431c30e1e894a486a0df04
doc_id: 311496
cord_uid: seehb6f2

Drug discovery is the practice of identifying chemical entities with activities useful for treating human diseases. Despite substantial advancements in biotechnologies such as assays for detecting promising hits and computational methods for identifying targets to pursue, the success rate of novel therapeutics in the clinic is rapidly declining. The two most common reasons for drug attrition in clinical trials are efficacy, in that the drug is not capable of treating the disease, and safety, in which the compound is too toxic to patients and does not outweigh any purported benefits. Here we describe the use of an integrated human interactome network to describe the complete picture of drug behavior in biological systems and lead to more promising therapeutic candidate generation. The Computational Analysis of Novel Drug Opportunities (CANDO) platform for shotgun multiscale drug discovery, repurposing, and design was enhanced to include drugs/compounds, proteins, diseases/indications, Gene Ontology entities, and drug side effects, accompanied with various known associations between them, and interactomic signatures were generated for all compounds using the node2vec algorithm for the purpose of relating them in the context of diseases for which they are approved. The results indicate there is significant biological information available in the side effect profile of a drug and they can be used to better relate drugs in terms of their therapeutic behavior. Side effects were also predicted for all compounds in the platform; known drug-side effect associations were recovered at rates ten times higher than what can be expected with random chance. The network architecture was also investigated in the context of protein pathways, where drug distance to various pathways served as the features for input to a random forest machine learning model in the context of indications they are associated to treat, with interesting results highlighted for mental disorders and cancer metastasis. This pipeline highlights the ability of CANDO to accurately relate drugs in a multitarget interactomic context, and paves the way for predicting novel putative drug candidates using the information gleaned from not only their side effect profiles, but their impacts on protein pathways as well. Significance Statement Our study outlines the capability of our drug discovery, repurposing, and design platform known as CANDO to more accurately describe small molecule therapeutic behavior in biological systems via the use of heterogeneous networks. This includes the ability to predict indications as well as side effects for compounds without clinical data, ultimately advancing the science of drug discovery.

Indication benchmarking ADR prediction

Drug-pathway distance + random forest models All compounds with unknown ADR profiles Interactomic signatures via node2vec

Re-integration to create ADR enhanced interactomic signatures Database mapping + Drug-ADR filtering + Compoundprotein interaction scoring Fig. 1 . Overview of the CANDO interactomic signature pipeline and analyses. Several biomedical databases were integrated into a unified network architecture after matching the identifiers in these databases to primarily drugs/compounds from DrugBank and proteins from the PDB and/or UniProt. Prior to integration, filtering of drug-ADR associations from the OFFSIDES database was necessary due to redundancy with the indication mapping from the Comparative Toxicogenomics Database, and a compound-protein intertaction scoring normalization scheme was also devised to supplement the network with additional interactions (see Methods). The interatomic signatures generated from the node2vec algorithm of various permutations of the network were benchmarked to assess how well they relate drugs in the context of disease, as well as to predict ADR associations for compounds with unknown profiles. Finally, drug distance to pathways served as features for input into random forest machine learning models to gain insight into which of them are seemingly important for drug therapeutic mechanisms, which coupled with the results of the indication benchmarking proved these networks are superior to traditional CANDO pipelines for assessing drug-drug similarity/behavior in biological systems. , the association to that ADR was removed, signified by both Drug A and Drug B. But even further, this was repeated for any drug that shared a disease association with any drug from the originally matched disease, signified by Drug C. B) If the ADR and disease terms mapped to their respective SNOMED concepts and both of those mapped to the same upper-level SNOMED concept, using the is_a relations in the SNOMED hierarchy, the association was removed. This scheme was used to eliminate as many false positives as possible which in the network would be nonsensical relations.

"Heart disease" belong to "Disorder of cardiovascular system"). Similarly to the previous process, sets were created by grouping 101 all mapped SNOMED concepts of the ADRs and indications that belonged to the same upper level SNOMED concept; if a drug 102 was associated to both an indication and ADR of the same upper level class (excluding top level terms "Disease" and "Clinical 103 finding"), the ADR association was removed ( Figure 2B ). This culminated in 50,210 associations between 1,112 drugs and Compound-protein interaction scoring protocol. Interaction scores between each protein and compound structure were com-120 puted using an in-house bioanalytic docking protocol known as BANDOCK. This protocol relies on two main components to 121 assign a real-valued score between a compound and protein: 1) known or predicted binding sites on the protein, as well as the 122 ligands known to bind to these binding sites as determined by X-ray structures in the PDB, and 2) chemical fingerprinting 123 methods that identify the presence or absence of molecular substructures on a compound. The first component is handled 124 by the COACH algorithm of the I-TASSER suite, which utilizes a consensus scoring approach of three different methods to 125 score how similar the binding sites on the query protein are to the binding sites in the PDB. The output of COACH is a 126 list of binding sites, the ligands known to bind to them, and an associated score (Pscore) for each. To assign a score for a 127 compound-protein pair, the Sorenson-Dice coefficient between the ECFP4 chemical fingerprints of each ligand associated to 128 the predicted binding sites for the protein and the query compound (Cscore) are computed; the strongest matching ligand 129 D R A F T (Cscore closest to 1.0) is chosen and multiplied by the Pscore for the binding site to which this ligand is associated (Pscore 130

x Cscore). This process is iterated for all compound and protein pairs to generate proteomic interaction signatures for all 131 drugs/compounds in the library.

Benchmarking protocol. The main goal of the CANDO platform is to accurately describe drug/compound behavior, and the 133 primary protocol used to assess the performance of a particular pipeline utilizes the indication approvals extracted from the CTD 134 to determine how often drugs associated to the same indication are deemed 'similar' according to various thresholds/cutoffs.

In the traditional pipeline, similarity of two compounds is calculated by comparing the scores in their proteomic interaction 136 signatures using the root-mean-square-deviation (RMSD) metric. This is repeated iteratively for all pairs in the library, 137 resulting in each having a list of compounds ranked by decreasing similarity. For each drug approved for a given indication, 138 the benchmarking protocol averages how many times another drug associated to that indication is found within a certain Further, smaller compounds tend to be favored by the ECFP4 fingerprint, while many others structurally resemble ligands 151 commonly co-crystallized with proteins in the PDB, both of which inflate their Cscores. In addition, well studied proteins like 152 cancer targets or kinase families also tend to be overrepresented in the PDB and therefore have greater Pscores from COACH, 153 as well as increased ligand diversity as a consequence. Since the Pscore from COACH implicitly measures confidence in the 154 binding site and therefore its associated ligand, simply considering only the Cscore (as opposed to multiplying it by the Pscore) 155 during the BANDOCK scoring protocol would 1) disregard a significant portion of the embedded evolutionary information 156 and 2) reduce the discernability between a compound with the same matching ligand for multiple proteins. Therefore, a which were connected to each other via protein-protein interactions from the String database as well as to protein pathways from the Reactome database. Protein annotations to Gene Ontology terms were extracted from UniProt as well. Proteins were mapped to diseases using the DisGeNET database, with additional diseases being sourced from the Comparative Toxicogenomics Database. Compound and drug structures were downloaded from DrugBank in addition to known protein-drug interactions, which was further supplemented using our BANDOCK interaction scoring protocol. Finally, side effects, or adverse drug reactions, for drugs were extracted from the SIDER and Offsides databases. Everything in black was an already-existing entity or relation in CANDO, whereas everything in red signifies a novel association for this network-based analyses and constitutes most of the connections between these entities.

ADR was present, the frequency of the ADR within the library, the size of the compound library, and the cutoff X using the 188 hypergeometric distribution. The ADRs are ranked by the probability, which represents the chance of randomly selecting at 189 least that many compounds associated to the ADR without replacement in X trials. The top 100 adverse drug reaction (ADRs) predictions for all 12,951 compounds in the CANDO library were generated using a consensus voting scheme. The ADRs associated to the most similar compounds, based on the similarity of their interactomic signatures generated using node2vec in a network devoid of all ADR associations, within a determined cutoff to a query compound were counted; the predictions are ranked by the probability computed using the hypergeometric distribution based on how many times the ADR was associated to the compounds most similar to the query, the number of ADRs present in the platform, and how many most similar compounds were inspected. Average precision was calculated at a given rank K by averaging the precision@K for all drugs with known ADRs (1171). The predictions generated using a cutoff of top 5% (647; orange) have lower average precision across all ranks compared to those generated using a cutoff of top 10% (1295; blue), yet both are 10-fold more precise on average than what is expected at random (red). The predictions using a cutoff of 25% (3238; purple) had higher precision at early ranks, peaking at rank 10, but significantly decreased at progressive ranks. Similarly, aside from rank 1, the average precision of the top 10% lists peaks at rank 18 and steadily declines thereafter, while the top 5% lists peak earlier at rank 12; this is likely due to the scarcity of drugs with known ADR associations in the full library. The dramatic increase on the random expected average precision for all sets of predictions indicates the interactomic signatures capture compound behavior effectively.

with a mean top10 AIA of 33.8% versus 27.6% (22.5% of %). In addition, a slight drop in performance was observed for the was computed for all ranks between 1 and 100 and averaged at each rank for all drugs with existing ADR associations from 226 OFFSIDES and SIDER 4. Aside from rank 1, which is the maximum average precision for the top 5 and 10% cutoffs, the peak 227 average PR@K was at rank 10 for the top25% cutoff; however, due to a bias discovered in the drug-indication mapping with 228 disproportionate impact on benchmarking accuracy (see below), for further analyses we selected the top10% cutoff due to its 229 better performance at higher numerical ranks. Its peak performance was at rank 18; rounded this up to the top 25 ADRs due 230 to comparable performance and associated these top ADRs to all compounds in CANDO with no ADR associations. For drugs 231 with existing ADRs that totaled fewer than 25, the ADRs were iterated in rank order until 25 unique ADRs were associated to 232 the drug. In addition to this top25 set, another set of all 100 ADR predictions were extracted in the same way for comparison.

The ability of different CANDO pipelines to accurately determine similarity of drugs known to treat the same indications was assessed using a hold-one-out benchmarking scheme on a per indication basis. All indication accuracies are averaged to compute the average indication accuracy (AIA; blue), while the number of indications with a non-zero accuracy, or indication coverage, is also counted (IC; red). The performance of the proteomic signature pipeline using a library of 8,385 human proteins and the ECFP4 molecular fingerprint pipeline are depicted and compared to the human interactome network pipeline, which uses the node2vec algorithm to output continuous value low dimensional embeddings based on connectivity of the heterogeneous biological network. The network pipeline also featured a set of the top 25 predicted drug-ADR associations for all compounds generated using a consensus voting scheme (see Methods). The AIA of this interactomic pipeline of 28.1% exceeds those of the proteomic signature and ECFP4 fingerprint pipelines of 20.7% and 23.6%, respectively, and is over five times that of the random control value of 5.3% (dashed blue). The same is true for IC where the ADR enhanced interactomic signatures achieve 57.2%, amounting to 97 additional indications for which there is a non-zero accuracy (out of 1,588), with a random control expected value of 28.3% (dashed red). This further indicates the interactomic signatures are capturing compound behavior more effectively than the less dynamic proteomic signature and fingerprint pipelines, and demonstrates that considering compound-protein interactions in the their complete biological context is beneficial for understanding their therapeutic mechanisms.

in the approved sublibrary were extracted and subjected to the benchmarking protocol as before. The top25 ADR network Disorders. The proteomic signatures and fingerprints do, however, outperform the interactomic signatures (lined blue and red, respectively) in Infections. Given that drugs treating infectious disease typically target pathogenic proteins, which are not included in the human interactome network, this performance is not surprising. The proteomic signature pipeline achieving significantly better performance, despite being composed of interactions with human proteins, is a phenomenon observed in previous CANDO publications in which the increase in the total number of proteins in an interaction signature leads to predictable increases in accuracy, most likely due to an increase in the coverage of the protein fold space (24). Coupled with the substantial increases in accuracy for complex diseases like cancer and psychiatric disorders, which have various and sometimes poorly understood etiologies, it is apparent that the interactomic signatures are capturing drug behavior beyond just their immediate protein targets, but in the entire context of interactions in which they are situated in biological systems.

to which 147 indications used for benchmarking belong. The proteomic signature and fingerprint pipelines achieved higher 257 accuracies for 53 (p = 3e-12) and 58 (p = 1e-10) of these indications, respectively, compared to the interactomic signatures. these drug-indication pairs were extracted for the top two (distinct) indications, "Mental Disorders" and "Neoplasm Metastasis", 277 with their top 5 non-redundant pathways listed in Table 1 and Table 2 , respectively.

Even though the initial benchmarking results using signatures derived from the network with incomplete ADR associations were identifying a correlation between drugs with well characterized side effect profiles and the number of indications for which 283 they are approved, regardless of the exact ADRs to which they were associated; this is evidenced by the relative diminished 284 impact the ADR associations had on benchmarking accuracy using the sublibrary of drugs with at least one ADR association 285 compared to the the equivalent networks without ADRs. The tremendous impact the ADRs have on benchmarking indication 286 accuracies, and therefore describing drug behavior in totality, is likely due to 1) the sheer number of compound "effects" that 287 are added by the ADR associations being nearly six times greater than those available in the indication mapping from the 288 CTD and 2) an increase in granularity for phenotypic outcomes after exposing these compounds to biological systems. The

former is an important limitation of most drug-indication prediction methods, i.e. a lack of a significant amount of positive 290 samples from which we can glean information about their mechanisms. The addition of the tens of thousands of ADRs for 291 drugs in the study provided a significant boost in direct phenotypic outcomes. The latter can range anywhere from routine 292 diagnostic findings, such as "Blood urea abnormal", which is likely due to impacts on one or a few protein pathways, to higher 293 level ADRs, such as "stomach cramps" or "headache", which are likely due to multiple contributing pathways. This will be 294 explored in a future work in which the pathways responsible for causing ADRs will be extracted in a similar manner to how 295 they were for the indications in this study, and clustered based on what pathways are seemingly contributing to those outcomes.

for which they are therapeutic. The proteomic signature pipeline achieving significantly better performance for indications, despite also not containing any pathogenic protein structures in its signatures, is a phenomenon observed in previous CANDO

3. M Hay, DW Thomas, JL Craighead, C Economides, J Rosenthal, Clinical development success rates for investigational drugs. Nat. biotechnology 32, 40-51 (2014).

New drugs cost us [dollar] 2.6 billion to develop

Clinical development success rates 2006-2015

Estimation of clinical trial success rates and related parameters

Trends in modern drug discovery. New Approaches to Drug Discov

Imatinib-an overview in Hematology Meeting Reports

Treatment of hypereosinophilic syndrome with imatinib mesilate

Treatment of inoperable gastrointestinal stromal tumor (gist) with imatinib (glivec, gleevec)

Imatinib mesylate in the treatment of systemic mastocytosis: a phase ii trial

Exploiting the promiscuity of imatinib

The reductionist paradox: are the laws of chemistry and physics sufficient for the discovery of new drugs?

Phenotypic screens as a renewed approach for drug discovery. Drug discovery today

Treatment resistant depression: a multi-scale

Systems biology primer: the basic methods and approaches

Systems biology in drug discovery and development. Drug discovery today

Network-based technologies for early drug discovery

Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review

Atomnet: a deep convolutional neural network for bioactivity prediction in structure-based drug discovery

Bioinformatics approaches for anti-cancer drug discovery

Inferring protein domains associated with drug side effects based on drug-target interaction network

Relating essential proteins to drug side-effects using canonical component analysis: a structure-based approach

Drug side-effect prediction based on the integration of chemical and biological spaces

Cando and the infinite drug discovery frontier

Multiscale modelling of relationships between protein classes and drug behavior across all diseases using the cando platform. Mini reviews medicinal chemistry 390 15

Exploring polypharmacology in drug discovery and repurposing using the cando platform

Exploration of interaction scoring criteria in the cando platform

Identifying protein features responsible for improved drug repurposing accuracies using the cando platform: Implications for drug design

Fingerprinting cando: Increased accuracy with structure-and ligand-based shotgun drug repurposing

Multiscale virtual screening optimization for shotgun drug repurposing using the cando platform

py: Open source software for predictive bioanalytics of large scale drug-protein-disease data

Combating ebola with repurposed therapeutics using the cando platform

Shotgun drug repurposing biotechnology to tackle epidemics and pandemics

The gene ontology (go) database and informatics resource

Gene ontology consortium: going forward

The gene ontology resource: 20 years and still going strong

node2vec: Scalable feature learning for networks in Proceedings of the 22nd ACM SIGKDD international conference on Knowledge discovery and data mining

Drugbank 5.0: a major update to the drugbank database for 2018

The protein data bank

Rcsb protein data bank: biological macromolecular structures enabling research and education in fundamental biology, biomedicine, biotechnology and energy

I-tasser server for protein 3d structure prediction

Automated protein structure modeling in casp9 by i-tasser pipeline combined with quark-based ab initio folding and fg-md-based structure refinement

The i-tasser suite: protein structure and function prediction

Uniprot: a worldwide hub of protein knowledge

Sifts: updated structure integration with function, taxonomy and sequences resource allows 40-fold increase in coverage of structure-based annotations for proteins

Sifts: structure integration with function, taxonomy and sequences resource

Hhblits: lightning-fast iterative protein sequence searching by hmm-hmm alignment

Comparative toxicogenomics database (ctd): update 2021

Disgenet: a comprehensive platform integrating information on human disease-associated genes and variants

Medical subject headings (mesh)

The sider database of drugs and side effects

Data-driven prediction of drug effects and interactions

The medical dictionary for regulatory activities (meddra)

The unified medical language system (umls): integrating biomedical terminology

Snomed-ct: The advanced terminology and coding system for ehealth

The reactome pathway knowledgebase

String v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets

Dopamine: receptors, functions, synthesis, pathways, locations and mental disorders: review of literatures

Genetic polymorphisms of serotonin and dopamine transporters in mental disorders

Development of allosteric modulators of gpcrs for treatment of cns disorders

Novel therapeutic gpcrs for psychiatric disorders

Potential utility of biased gpcr signaling for treatment of psychiatric disorders

Update on the implication of potassium channels in autism: K+ channelautism spectrum disorder

Transient potassium channels: Therapeutic targets for brain disorders

A review of potassium channels in bipolar disorder

Serotonin receptor 2c and mental disorders: genetic, expression, and rna editing studies

The engagement of brain cytochrome p450 in the metabolism of endogenous neuroactive substrates: a possible role in mental disorders

S-adenosylmethionine in combination with decitabine shows enhanced anti-cancer effects in repressing breast cancer growth and 441 metastasis

Methyl donor s-adenosylmethionine (sam) supplementation attenuates breast cancer growth, invasion, and metastasis in vivo

S-adenosylmethionine blocks osteosarcoma cells proliferation and invasion in vitro and tumor metastasis in vivo: therapeutic and diagnostic clinical applications

Specialized pro-resolving mediators mitigate cancer-related inflammation: role of tumor-associated macrophages and therapeutic 447 opportunities

Control of breast cancer through the resolution of inflammation

Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions

Dietary aflatoxin exposure and chemoprevention of cancer: a clinical review

Aflatoxin b1 and m1: Biological properties and their involvement in cancer development

Aflatoxin and liver cancer

Drugs that target lipoxygenases and leukotrienes as emerging therapies for asthma and cancer

On the biosynthesis and biological role of eoxins and 15-lipoxygenase-1 in airway inflammation and hodgkin lymphoma

Effects of eicosatrienoic acid (20: 3 n-9, mead's acid) on some promalignant-related properties of three human cancer cell lines

Deregulating the cyp2c19/epoxy-eicosatrienoic acid-associated fabp4/fabp5 signaling network as a therapeutic approach for metastatic triple-negative 458 breast cancer

Fatty acid oxidation: An emerging facet of metabolic transformation in cancer

Long-chain fatty acyl-coa synthetase 1 promotes prostate cancer progression by elevation of lipogenesis and fatty acid beta-oxidation

Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer

A next generation connectivity map: L1000 platform and the first 1,000,000 profiles

The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease

Identifying disease-gene associations using a convolutional neural network-based model by embedding a biological knowledge graph with entity descriptions

A survey of network representation learning methods for link prediction in biological network

A vectorized relational graph convolutional network for multi-relational network alignment

Transnet: Translation-based network representation learning for social relation extraction

The approved dose of ivermectin alone is not the ideal dose for the treatment of covid-19

Ivermectin as a potential covid-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens